CN110652004A - Nutritional composition for preventing and treating depression and preparation method and application thereof - Google Patents
Nutritional composition for preventing and treating depression and preparation method and application thereof Download PDFInfo
- Publication number
- CN110652004A CN110652004A CN201910811571.6A CN201910811571A CN110652004A CN 110652004 A CN110652004 A CN 110652004A CN 201910811571 A CN201910811571 A CN 201910811571A CN 110652004 A CN110652004 A CN 110652004A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- nutritional composition
- vitamin
- polygala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 39
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- 201000009916 Postpartum depression Diseases 0.000 claims abstract description 22
- 241000208966 Polygala Species 0.000 claims abstract description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 9
- 229930195729 fatty acid Natural products 0.000 claims abstract description 9
- 239000000194 fatty acid Substances 0.000 claims abstract description 9
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 239000010017 yuan zhi Substances 0.000 claims abstract description 8
- 229930003761 Vitamin B9 Natural products 0.000 claims abstract description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 5
- 235000019159 vitamin B9 Nutrition 0.000 claims abstract description 5
- 239000011727 vitamin B9 Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 33
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 17
- 241001080798 Polygala tenuifolia Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 10
- 108010076119 Caseins Proteins 0.000 claims description 9
- 108010073771 Soybean Proteins Proteins 0.000 claims description 9
- 108010046377 Whey Proteins Proteins 0.000 claims description 9
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- 235000021119 whey protein Nutrition 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 235000021323 fish oil Nutrition 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 3
- 235000021552 granulated sugar Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 102000011632 Caseins Human genes 0.000 claims 1
- 229940001941 soy protein Drugs 0.000 claims 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 4
- 230000036542 oxidative stress Effects 0.000 abstract description 4
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 abstract description 4
- 230000008451 emotion Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 2
- 206010010904 Convulsion Diseases 0.000 abstract description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 229930003451 Vitamin B1 Natural products 0.000 abstract description 2
- 229930013930 alkaloid Natural products 0.000 abstract description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 239000000460 chlorine Substances 0.000 abstract description 2
- 229910052801 chlorine Inorganic materials 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000036461 convulsion Effects 0.000 abstract description 2
- 229910052742 iron Inorganic materials 0.000 abstract description 2
- 239000011777 magnesium Substances 0.000 abstract description 2
- 229910052749 magnesium Inorganic materials 0.000 abstract description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 abstract description 2
- -1 oligosaccharide ester Chemical class 0.000 abstract description 2
- 239000011591 potassium Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 229930182490 saponin Natural products 0.000 abstract description 2
- 150000007949 saponins Chemical class 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 229960003495 thiamine Drugs 0.000 abstract description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract description 2
- 235000010374 vitamin B1 Nutrition 0.000 abstract description 2
- 239000011691 vitamin B1 Substances 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 19
- 229930006000 Sucrose Natural products 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 239000005720 sucrose Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 239000005018 casein Substances 0.000 description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 8
- 235000021240 caseins Nutrition 0.000 description 8
- 235000019710 soybean protein Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229930003779 Vitamin B12 Natural products 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 235000019163 vitamin B12 Nutrition 0.000 description 4
- 239000011715 vitamin B12 Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 235000020926 24-h fasting Nutrition 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 244000195895 saibo Species 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a nutritional composition for preventing and treating depression, a preparation method and an application thereof, wherein the nutritional composition comprises the following components in parts by weight: 5-10 parts of keel extract, 3-5 parts of polygala extract, 10-20 parts of protein, 10-20 parts of fatty acid, 45-65 parts of carbohydrate, 2-4 parts of tryptophan, 0.1-0.2 part of vitamin C and 2-2 parts of vitamin B11; wherein the fatty acid can refresh the brain, has sensitive response and can enhance intelligence; vitamin C regulates and controls central nervous oxidative stress system and regulates cerebral emotion; vitamin B1 can prevent mitochondrial dysfunction and chronic oxidative stress; substances such as saponin, xanthone, oligosaccharide ester and alkaloid in cortex et radix Polygalae extract, calcium carbonate and microelements such as iron, potassium, sodium, chlorine and magnesium in Os Draconis extract can not only relieve convulsion and tranquilize, but also supplement nutrition required for puerperal delivery and promote puerperal recovery; therefore, the nutritional composition for preventing and treating depression provided by the invention can effectively relieve and treat postpartum depression through reasonable compatibility, and has no side effect.
Description
Technical Field
The invention relates to the technical field of foods, in particular to a nutritional composition for preventing and treating depression and a preparation method and application thereof.
Background
Puerperal Depression (PPD) refers to a psychological disorder characterized by a series of symptoms of depression, sadness, depression, crying, irritability, even suicidal or baby-killing tendency of a parturient after delivery, and is one of the most common types of puerperal mental syndromes, also known as postpartum depression.
The research at home and abroad finds that the postpartum depression affects the feeding and the development of the infants, destroys the harmony of the mothers and the infants, has certain influence on the infant temperament, and hinders the growth, cognition, emotion and behavior development of the infants. Every year, China has more than two thousand women in childbirth, wherein the incidence rate of postpartum depression is 5-20%, and the incidence rate of foreign postpartum depression is about 13%. Postpartum depression not only affects physical and mental health of puerperae and growth and development of newborn, but also destroys family and social harmony and stability.
At present, the means for clinically treating postpartum depression mainly adopts a drug therapy, wherein the drug therapy mainly adopts western medicines, but the western medicines for treating postpartum depression have no specific drugs, and the traditional drugs for treating postpartum depression such as 5-hydroxytryptamine reuptake inhibitors not only affect lactation, but also possibly cause Alzheimer's disease.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to overcome the defects that the products for treating postpartum depression in the prior art influence lactation and possibly cause Alzheimer's disease, so that the nutritional composition for preventing and treating depression, the preparation method and the application thereof are provided, postpartum depression can be effectively relieved and treated, and side effects are avoided.
Therefore, the invention provides the following technical scheme:
a nutritional composition for preventing and treating depression comprises the following components in parts by weight: 5-10 parts of keel extract, 3-5 parts of polygala extract, 10-20 parts of protein, 10-20 parts of fatty acid, 45-65 parts of carbohydrate, 2-4 parts of tryptophan, 0.1-0.2 part of vitamin C and 2-2 parts of vitamin B11.
Preferably, the nutritional composition consists of the following components in parts by weight: 5-6 parts of keel extract, 3-4 parts of polygala extract, 16-20 parts of protein, 15-20 parts of fatty acid, 45-55 parts of carbohydrate, 2-3 parts of tryptophan, 0.1-0.2 part of vitamin C and 2-2 parts of vitamin B11.
The fatty acid is fish oil or rapeseed oil.
The protein is whey protein, casein and soybean protein, wherein the mass ratio of the whey protein, the casein and the soybean protein is 0.5-1:0.5-1: 1.
The carbohydrate is maltodextrin or white granulated sugar.
The invention also provides a preparation method of the nutritional composition for preventing and treating depression, which comprises the following steps:
preparation of polygala root extract: pulverizing cortex et radix Polygalae, sieving, extracting, filtering, and spray drying to obtain cortex et radix Polygalae extract powder;
weighing: weighing the components in selected parts for later use;
mixing: mixing the above powders in equal amount to obtain the nutritional composition;
wherein, the extraction in the preparation step of the polygala tenuifolia extract refers to adding n-butyl alcohol and 95% ethanol for reflux extraction for three times, each time for 1-3h, wherein the volume ratio of the n-butyl alcohol to the 95% ethanol is 0.2-0.5: 1-3.
In the preparation step of the polygala tenuifolia extract, the mass volume ratio of the crushed and sieved polygala tenuifolia powder to the added n-butanol and 95% ethanol is 1 g: 20-30 ml.
The step of pulverizing and sieving in the preparation of the polygala tenuifolia extract refers to pulverizing and sieving with a 20-80 mesh sieve;
and/or the mixing time in the mixing step is 40-50min, and the mixing frequency is 20-45 rpm.
The inlet temperature of spray drying in the preparation step of the polygala tenuifolia extract is 90-100 ℃, the outlet temperature is 40-50 ℃, and the feeding rate is 15-20 ml/min.
The invention also provides application of the nutritional composition for preventing and treating depression or the nutritional composition prepared by the preparation method of the nutritional composition for preventing and treating depression in treatment of postpartum depression.
The technical scheme of the invention has the following advantages:
1. the nutrient composition for preventing and treating depression, provided by the invention, has the advantages that fatty acid enables people to be clear, the response is sensitive, the intelligence is enhanced, the depressed mood is eliminated, and the spirit is stimulated; vitamin C can regulate and control the abnormality of the central nervous system oxidative stress system caused by environmental stress, and simultaneously, vitamin C is also an important coenzyme and can participate in the metabolic process from tyrosine to adrenaline in the central nervous system to regulate the cerebral emotion; tryptophan is metabolized to generate 5-hydroxytryptamine, so that the concentration of the 5-hydroxytryptamine in blood is increased, and depression symptoms are improved; vitamin B1 can prevent mitochondrial dysfunction and chronic oxidative stress; substances such as saponin, xanthone, oligosaccharide ester and alkaloid in the polygala tenuifolia extract, calcium carbonate in the keel extract, and microelements such as iron, potassium, sodium, chlorine, magnesium and the like are combined with protein and carbohydrate in the components, so that not only can the convulsion relieving and the nerve soothing be realized, but also the nutrition required by postpartum can be supplemented, and the postpartum recovery is promoted; therefore, the nutritional composition provided by the invention can effectively relieve and treat postpartum depression through scientific and reasonable compatibility, and has no side effect.
2. According to the preparation method of the nutritional composition for preventing and treating depression, the mixed solvent of n-butanol and ethanol is adopted for extraction in the polygala tenuifolia extraction step, compared with the simple ethanol extraction, more effective components are obtained, the postpartum depression can be effectively relieved and treated, and no side effect is generated.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 shows the results of sucrose consumption in mice in the experimental examples of the present invention;
FIG. 2 shows the experimental results of forced swimming of a mouse in the experimental example of the present invention;
FIG. 3 shows the results of the experiment of feeding incubation period in the strange environment of mice in the experimental example of the present invention;
FIG. 4 shows the results of the experiment of food intake of the strange environment of the mouse in the experimental example of the present invention.
Description of the drawings:
compared with the blank control group, the composition of the composition,*P＜0.05，**p is less than 0.01; compared with the positive control group, the composition has the advantages that,#P＜0.05，##p is less than 0.01; compared with the model control group,$P＜0.05，$$p is less than 0.01; in comparison with the comparative example group,&P＜0.05，&&P＜0.01。
Detailed Description
The following examples are provided to further understand the present invention, not to limit the scope of the present invention, but to provide the best mode, not to limit the content and the protection scope of the present invention, and any product similar or similar to the present invention, which is obtained by combining the present invention with other prior art features, falls within the protection scope of the present invention.
The examples do not show the specific experimental steps or conditions, and can be performed according to the conventional experimental steps described in the literature in the field. The reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially.
The Os Draconis extract was obtained from Saibo science and technology, Inc. of Yuan Cheng Sai province, Hubei.
Example 1
The present example provides a nutritional composition and a method of making the same.
Preparation of polygala root extract: pulverizing 20g cortex et radix Polygalae, sieving with 20 mesh sieve, adding 66ml n-butanol and 334ml 95% ethanol, reflux extracting for 3 times, each for 1 hr; filtering, and spray drying the filtrate at inlet temperature of 90 deg.C, outlet temperature of 50 deg.C and feeding rate of 15ml/min to obtain cortex et radix Polygalae extract powder;
weighing: weighing 6g of keel extract, 4g of polygala extract, 5.3g of whey protein, 5.3g of casein, 5.3g of soybean protein, 15g of fish oil, 55g of maltodextrin, 3g of tryptophan, 0.2g of vitamin C and vitamin B12 g for later use;
mixing: mixing the above powders according to an equivalent incremental method, wherein the mixing time is 40min, and the mixing frequency is 45 rpm; thus obtaining the nutritional composition.
Example 2
The present example provides a nutritional composition and a method of making the same.
Preparation of polygala root extract: pulverizing 20g cortex et radix Polygalae, sieving with 80 mesh sieve, adding 37ml n-butanol and 563ml 95% ethanol, reflux extracting for 3 times, each for 3 hr; filtering, and spray drying the filtrate at inlet temperature of 100 deg.C, outlet temperature of 40 deg.C and feeding rate of 20ml/min to obtain cortex et radix Polygalae extract powder;
weighing: weighing 5g of keel extract, 5g of polygala extract, 2.5g of whey protein, 2.5g of casein, 5g of soybean protein, 10g of fish oil, 65g of maltodextrin, 2g of tryptophan, 0.1g of vitamin C and vitamin B12 g for later use;
mixing: mixing the above powders according to an equivalent incremental method for 50min at a mixing frequency of 20 rpm; thus obtaining the nutritional composition.
Example 3
The present example provides a nutritional composition and a method of making the same.
Preparation of polygala root extract: pulverizing 30g cortex et radix Polygalae, sieving with 60 mesh sieve, adding n-butanol 250ml and 95% ethanol 500ml, reflux extracting for 3 times, each for 1.5 hr; filtering, and spray drying the filtrate at inlet temperature of 95 deg.C, outlet temperature of 45 deg.C and feeding rate of 20ml/min to obtain cortex et radix Polygalae extract powder;
weighing: weighing 10g of keel extract, 3g of polygala extract, 4g of whey protein, 8g of casein, 8g of soybean protein, 20g of fish oil, 45g of white granulated sugar, 4g of tryptophan, 0.2g of vitamin C and 11 g of vitamin B for later use;
mixing: mixing the above powders according to an equivalent progressive method, wherein the mixing time is 45min, and the mixing frequency is 30 rpm; thus obtaining the nutritional composition.
Example 4
The present example provides a nutritional composition and a method of making the same.
Preparation of polygala root extract: pulverizing 20g cortex et radix Polygalae, sieving with 50 mesh sieve, adding 71ml n-butanol and 429ml 95% ethanol, reflux extracting for 3 times, each for 1.5 hr; filtering, and spray drying the filtrate at inlet temperature of 95 deg.C, outlet temperature of 45 deg.C and feeding rate of 20ml/min to obtain cortex et radix Polygalae extract powder;
weighing: weighing 6g of keel extract, 4g of polygala extract, 8g of whey protein, 4g of casein, 8g of soybean protein, 15g of rapeseed oil, 55g of maltodextrin, 3g of tryptophan, 0.2g of vitamin C and 12 g of vitamin B for later use;
mixing: mixing the above powders according to an equivalent progressive method, wherein the mixing time is 45min, and the mixing frequency is 30 rpm; thus obtaining the nutritional composition.
Comparative example 1
The present comparative example provides a nutritional composition and a method of making the same.
Weighing: weighing 5.3g of whey protein, 5.3g of casein, 5.3g of soybean protein, 15g of fish oil, 55g of maltodextrin, 3g of tryptophan, 0.2g of vitamin C and vitamin B12 g for later use;
mixing: mixing the above powders according to an equivalent incremental method, wherein the mixing time is 40min, and the mixing frequency is 45 rpm; thus obtaining the nutritional composition.
Comparative example 2
The present comparative example provides a nutritional composition and a method of making the same.
Preparation of polygala root extract: pulverizing 20g cortex et radix Polygalae, sieving with 20 mesh sieve, adding 95% ethanol 400ml, reflux extracting for 3 times, each for 1 hr; filtering, and spray drying the filtrate at inlet temperature of 90 deg.C, outlet temperature of 50 deg.C and feeding rate of 15ml/min to obtain cortex et radix Polygalae extract powder;
weighing: weighing 6g of keel extract, 4g of polygala extract, 5.3g of whey protein, 5.3g of casein, 5.3g of soybean protein, 15g of fish oil, 55g of maltodextrin, 3g of tryptophan, 0.2g of vitamin C and vitamin B12 g for later use;
mixing: mixing the above powders according to an equivalent incremental method, wherein the mixing time is 40min, and the mixing frequency is 45 rpm; thus obtaining the nutritional composition.
Experimental examples investigation of the nutritional composition of the invention for the prevention and treatment of postpartum depression
1. Materials and methods
1.1 Experimental animals
56 clean-grade healthy adult female Balb/c mice, weighing 18-24g, were provided by the military medical academy of sciences, and were used for the experiments after 1 week of adaptive feeding. Wherein the room temperature of the animal room is 25 ℃, the humidity is 45%, the light and shade alternation time is 12h, and water is freely fed.
1.2 compositions and reagents
Composition (A): the nutritional composition prepared in example 1, the nutritional composition prepared in comparative example 1; the nutritional composition prepared in comparative example 2; the forced swimming video analysis system is purchased from Shanghai Soft-Longing science and technology development company, and the sucrose is purchased from national medicine group chemical reagent company, Inc.
2. Experimental methods
2.1 animal groups
The mice were randomly divided into 2 groups, 8 blank control groups, 48 model groups, no stress was applied to the blank control groups, and the model group mice were given a total of 6h of restraint stress stimulation from 11 am to 5 pm daily. And after 3 weeks, mating and feeding the pre-pregnancy stress group in 1 male and female cages. After about 4 weeks, the mother mice were parturied, as a model group.
2.2 Experimental groups
Randomly dividing the model group into 6 groups, wherein each group comprises 8 models; the blank control group is unchanged and is specifically divided into the following groups:
firstly, a blank control group is filled with distilled water with the same volume;
secondly, the model control group is drenched with distilled water with the same volume;
③ the positive control group, 21 days after delivery, the composition prepared in the comparative example 1 is administered with 100mg/kg for equal volume;
fourthly, a comparative example group is given the composition prepared in the comparative example 2 after 21 days, and the composition is irrigated with 100mg/kg of the same volume;
administering the composition prepared in example 1 to a low dose group 21 days after delivery, and drenching the composition at 50mg/kg with the same volume;
sixthly, the composition prepared in the example 1 is administrated 21 days after delivery, and the composition is infused with 100mg/kg of the same volume;
seventhly, in the high dose group, the composition prepared in example 1 was administered at 150mg/kg by instillation in an equal volume once a day.
2.3 sucrose consumption test
Two bottles of 2% sucrose solution were given to each stressed group and blank group for adaptation 3d prior to pre-pregnancy stress. After the mice in each group were fasted for 18h, they were raised in a single cage, and each cage was given a bottle of 2% sucrose solution and a bottle of tap water, and the sucrose consumption was observed for 2 h. The percentage of sucrose consumption is calculated by the formula: sucrose consumption/% ═ [ (sucrose intake)/(sucrose intake + water intake) ] × 100%.
2.4 forced swimming test
The mice in each group are respectively placed into a glass beaker, and the water temperature is kept at 24-26 ℃. Immediately after allowing the mice to swim for 2min, observations were started to record the total immobility time of the mice within the next 4 min: i.e. the mice stopped struggling in the water, or were floating, with only a small amount of limb movement time.
2.5 feeding experiment in strange Environment
After fasting for 24h, the mice are respectively placed in a new squirrel cage, padding with the thickness of about 1cm is paved at the bottom, and weighed grains are placed in the center. After placement, mice were tested for the latency to begin feeding. The criteria for feeding is that the mouse begins to chew on the food rather than merely smell or fiddle with it. The incubation period and the weight of food consumed were measured and defined as 5min if the mice did not eat within 5 min. Mice were placed in the same position and in the same direction each time in the experiment. The food intake in unit time is calculated by the following formula: the food intake (g) per unit time is 5min, the weight (g) of the consumed grain/the weight (g) of the mouse.
2.6 data analysis
The data obtained from the experiment are all used
Data are expressed by performing one-way analysis of variance on data between multiple groups by the sps 20.0 statistical analysis software, and data comparison between two groups is performed by adopting T test analysis. P<0.05 means statistically significant, P<0.01 is a significant difference, P>0.05 indicated no statistical significance.
3. Results of the experiment
3.1 sucrose consumption test results
The results from fig. 1 show that: the sucrose consumption percentage of the model control group is obviously reduced (P is less than 0.01) compared with that of the blank control group; the high, medium and low dose groups, the positive control group and the comparative control group have significant difference (P <0.05 or P <0.01) compared with the model control group; the difference of the high-dose group, the medium-dose group and the low-dose group is obvious compared with the positive control group, and P is less than 0.01; the difference between the high-dose group and the medium-dose group is obvious compared with the comparative example group, and P is less than 0.01; the effect of the nutritional composition for preventing and treating postpartum depression is better than that of a positive control group and a comparative group.
3.2 forced swimming test results
The results in fig. 2 show that the immobility duration of the mice is significantly increased in the model control group compared with the blank control group, and the model control group has significant difference compared with the blank control group, wherein P is less than 0.01; compared with a model control group, the high, medium and low dose groups, the positive control group and the comparative control group have obvious difference (P <0.05 or P < 0.01); the difference of the high-dose group, the medium-dose group and the low-dose group is obvious compared with the positive control group, and P is less than 0.01; the difference of the high-dose group, the medium-dose group and the low-dose group is obvious compared with the comparative example group, and P is less than 0.01; the nutritional composition has good effect of preventing and treating postpartum depression, and is superior to a positive control group and a comparative group.
3.3 results of feeding experiments in strange Environment
Compared with a blank control group, the incubation period of the model control group mice for feeding in a strange environment is obviously prolonged (P <0.01, shown in figure 3), and the food intake per unit time is obviously reduced (P <0.01, shown in figure 4); compared with the model control group, the high, medium and low dose groups, the positive control group and the comparative control group, the mice fed in strange environment has obviously prolonged incubation period (P <0.01, as shown in figure 3) and obviously reduced food intake per unit time (P <0.01, as shown in figure 4). The difference of the high-dose group, the medium-dose group and the low-dose group is obvious compared with the positive control group, P is less than 0.01, and the difference of the high-dose group, the medium-dose group and the low-dose group is obvious compared with the comparative example group (P is less than 0.05 or P is less than 0.01); the nutritional composition has good effect of preventing and treating postpartum depression, and is superior to a positive control group and a comparative group.
The percentage of sugar water consumption of mice in a 3-week postpartum model control group is obviously reduced, the hopeless immobility time in a forced swimming test is obviously increased, the latency is obviously prolonged and the unit food intake is reduced in a strange environment food intake test, so that the phenomena of anhedonia, interest reduction, behavior hopeless and anxiety accompanied are caused in postpartum depression model mice induced by pre-pregnancy stress, and the successful establishment of the model is indicated.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the spirit or scope of the invention.
Claims (10)
1. The nutritional composition for preventing and treating depression is characterized by comprising the following components in parts by weight: 5-10 parts of keel extract, 3-5 parts of polygala extract, 10-20 parts of protein, 10-20 parts of fatty acid, 45-65 parts of carbohydrate, 2-4 parts of tryptophan, 0.1-0.2 part of vitamin C and 2-2 parts of vitamin B11.
2. The nutritional composition according to claim 1, characterized by consisting of the following components in parts by weight: 5-6 parts of keel extract, 3-4 parts of polygala extract, 16-20 parts of protein, 15-20 parts of fatty acid, 45-55 parts of carbohydrate, 2-3 parts of tryptophan, 0.1-0.2 part of vitamin C and 2-2 parts of vitamin B11.
3. Nutritional composition according to claim 1 or 2, wherein the fatty acid is fish oil or rapeseed oil.
4. The nutritional composition according to claim 3, wherein the protein is whey protein, casein protein, and soy protein, wherein the mass ratio of the three is 0.5-1:0.5-1: 1.
5. The nutritional composition according to claim 4, wherein the carbohydrate is maltodextrin or white granulated sugar.
6. A method for preparing a nutritional composition for preventing and treating depression according to any one of claims 1 to 5, comprising the steps of:
preparation of polygala root extract: pulverizing cortex et radix Polygalae, sieving, extracting, filtering, and spray drying to obtain cortex et radix Polygalae extract powder;
weighing: weighing the components in selected parts for later use;
mixing: mixing the above powders in equal amount to obtain the nutritional composition;
wherein, the extraction in the preparation step of the polygala tenuifolia extract refers to adding n-butyl alcohol and 95% ethanol for reflux extraction for three times, each time for 1-3h, wherein the volume ratio of the n-butyl alcohol to the 95% ethanol is 0.2-0.5: 1-3.
7. The method according to claim 6, wherein the polygala tenuifolia extract is prepared by pulverizing sieved polygala tenuifolia powder, and adding n-butanol and 95% ethanol at a mass-to-volume ratio of 1 g: 20-30 ml.
8. The method according to claim 7, wherein the step of pulverizing and sieving the polygala tenuifolia extract is to pulverize and pass through a 20-80 mesh sieve;
and/or the mixing time in the mixing step is 40-50min, and the mixing frequency is 20-45 rpm.
9. The method according to any one of claims 6 to 8, wherein the inlet temperature of the spray drying in the step of preparing the polygala tenuifolia extract is 90 to 100 ℃, the outlet temperature is 40 to 50 ℃, and the feed rate is 15 to 20 ml/min.
10. Use of the nutritional composition for the prevention and treatment of depression according to any one of claims 1 to 5 or the nutritional composition for the prevention and treatment of depression according to any one of claims 6 to 9 in the treatment of postpartum depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910811571.6A CN110652004A (en) | 2019-08-29 | 2019-08-29 | Nutritional composition for preventing and treating depression and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910811571.6A CN110652004A (en) | 2019-08-29 | 2019-08-29 | Nutritional composition for preventing and treating depression and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110652004A true CN110652004A (en) | 2020-01-07 |
Family
ID=69036537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910811571.6A Pending CN110652004A (en) | 2019-08-29 | 2019-08-29 | Nutritional composition for preventing and treating depression and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110652004A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115721009A (en) * | 2021-08-25 | 2023-03-03 | 中国科学院上海营养与健康研究所 | Method, composition and application for relieving depression |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010133015A1 (en) * | 2009-05-21 | 2010-11-25 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
| CN102416148A (en) * | 2011-12-08 | 2012-04-18 | 南京海昌中药集团有限公司 | Medicine for treating depression, and preparation method and application thereof |
| CN103027299A (en) * | 2013-01-07 | 2013-04-10 | 易时亮 | Nutrition formulation for postpartum depression and use method of nutrition formulation |
-
2019
- 2019-08-29 CN CN201910811571.6A patent/CN110652004A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010133015A1 (en) * | 2009-05-21 | 2010-11-25 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
| CN102416148A (en) * | 2011-12-08 | 2012-04-18 | 南京海昌中药集团有限公司 | Medicine for treating depression, and preparation method and application thereof |
| CN103027299A (en) * | 2013-01-07 | 2013-04-10 | 易时亮 | Nutrition formulation for postpartum depression and use method of nutrition formulation |
Non-Patent Citations (4)
| Title |
|---|
| 卫生部: "卫生部关于进一步规范保健食品原料管理的通知", 《卫生部文件，卫法监发（2002）51号》 * |
| 李金龙: "《饮食营养与科学》", 31 July 2010, 北京：京华出版社 * |
| 第十一届全国人民代表大会常务委员会: "中国人民共和国食品安全法", 《中央政府门户网站》 * |
| 苗明三等: "《中药大辞典》", 31 March 2017, 太原：山西科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115721009A (en) * | 2021-08-25 | 2023-03-03 | 中国科学院上海营养与健康研究所 | Method, composition and application for relieving depression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104780781B (en) | The method adjusting the individual Corticosterone Level of psychological stress | |
| EP1767212B1 (en) | Plants of genus ampelopsis and extracts thereof for use in the treatment of sleep disorders | |
| CN102757508B (en) | A kind of Radix Ophiopogonis polysaccharide extract has the application in the foodstuff additive of weight losing function, healthcare products or medicine in preparation | |
| CN104780785A (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
| US20210000904A1 (en) | Novel use of maydis stigma extract in prophylaxis and therapy of sleep disorder | |
| US9167841B2 (en) | Tangerine peel extract and its preparation and application | |
| CN104719918A (en) | Composition for improving sleep quality and preparation of composition | |
| CN106492048A (en) | A kind of rush sleep preparation and preparation method thereof | |
| CN110433259A (en) | It is a kind of to intervene the Chinese medicine composition of obstruction of the circulation of vital energy constitution, broken wall composition and preparation method thereof | |
| CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
| CN111820414A (en) | Health food for improving sleep and preparation method thereof | |
| CN110652004A (en) | Nutritional composition for preventing and treating depression and preparation method and application thereof | |
| CN113040393A (en) | Nutritional formula for intervening anxiety and sleep disorder | |
| WO2016134563A1 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN111357891A (en) | Plant beverage containing artichoke and ginseng and preparation method thereof | |
| CN111249316A (en) | Preparation method and application of pure natural product for preventing and treating insomnia | |
| KR101256210B1 (en) | Pharmaceutical Compositions for Treating Anxiety | |
| CN109700973A (en) | A kind of regenerated Chinese medicine composition of promotion Hippocampal Neuron Cells | |
| CN111616357B (en) | GABA spleen-tonifying and nerve-soothing composition based on homology of medicine and food, preparation and application thereof | |
| CN103071080B (en) | Traditional Chinese medicine preparation for treating depressive disorder | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN111838666A (en) | Composition with auxiliary memory improving function and application thereof | |
| CN105982921A (en) | Composition for treating gout and application thereof | |
| TW201806612A (en) | Use of anisomeles indica in manufacture of medicament for anti-fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |
|
| RJ01 | Rejection of invention patent application after publication |